Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial

Brito, Milena Bastos; Ferriani, Rui Alberto; Meijers, Joost C. M.; García, Adolfo Cobo; Quintana, Silvana Maria; Sá, Marcos Felipe Silva de; Vieira, Carolina Sales

doi:10.1016/j.thromres.2012.03.029

Cited by 19 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The insertion of ENG implant during the immediate postpartum period was not associated with differences in lochia duration [175] or alteration in the maternal metabolism and hemostatic system (blood pressure, maternal, BMI, waist circumference, complete blood count, CRP, IL-6, TNF-alpha, lipid profile, fasting serum glucose) [176,177]; similarly, no increased rate of venous thromboembolism [178] or negative impact on bone turnover [179] were observed.…”

Section: Post-partum Implant Placementmentioning

confidence: 90%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved for reversible contraception. The etonogestrel (ENG) single rod dispositive has been widely employed in clinical practice, since it is a highly effective and safe contraceptive method. Abnormal menstrual bleeding is a common ENG side effect, representing the main reason for its premature discontinuation. Emerging evidence demonstrated that it is possible to extend the use of the ENG implant beyond the three-year period for which it is approved. The ENG implant could be an effective and discrete alternative to the IUD in young girls, such as post-partum/post-abortion. Implants should be inserted by trained skilled clinicians who previously provide adequate counselling about their contraceptive effect, benefits, and any possible adverse events. More studies are needed to validate the extended use of the ENG implant for up to 5 years.

show abstract

Section: Post-partum Implant Placementmentioning

confidence: 90%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Numerous studies have also documented the efficacy and safety of LARC (Bhathena and Guillebaud 2008;Brito et al 2012;Stoddard et al 2011). While there were previous fears about the suitability of LARC for adolescents, for immediate post-partum, and post-abortion insertions, ACOG guidelines now note that existing evidence does not substantiate these fears.…”

Section: The Use Of Larcmentioning

confidence: 99%

The Use of ACOG Guidelines: Perceived Contraindications to IUD and Implant Use Among Family Planning Providers

Philliber¹,

Hirsch²,

Brindis

et al. 2017

Matern Child Health J

View full text Add to dashboard Cite

SignificanceThe American College of Obstetricians and Gynecologists (ACOG) provides up to date guidelines for the use of longacting reversible contraception methods (LARC); however, there is limited information on how these guidelines are used by practitioners. In this paper, we describe the differences in providers' beliefs and practices before and after the release of the 2012 ACOG guidelines and how these might be contributing to the limited use of LARC in the US.

show abstract

“…En 2014 se publicó un estudio de casos y controles que evidenció que las mujeres que utilizaban un progestágeno inyectable, en su forma de acetato de medroxiprogesterona de depósito, tuvieron el doble de riesgo de presentar un primer episodio de TEV comparado con las mujeres del grupo control (OR 2.2, IC 95% 1.3 -4.0; 47 de 948 casos de TEV (5 %) y 23 de 902 controles (2.5%)) 14 . En este mismo trabajo el uso de progestágeno vía oral, el endoceptivo intrauterino liberador de levonorgestrel o el implante subdérmico de progestágeno solo, no se asociaron a un aumento significativo de riesgo de TEV.…”

Section: Métodos De Progestágenos úNicosunclassified

“…Los estudios observacionales han reportado de manera constante un aumento de 2 a 7 veces el riesgo de TEV en usuarias de ACHO en comparación con los no usuarias 2,16-22 , pero ese riesgo varía de acuerdo a la dosis y tipo de estrógeno y progestágeno utilizados 14,16,22 . Cuando se relaciona el riesgo de TEV con el tipo y dosis de estrógeno o progestágeno, es de 1.5 a 2 veces mayor en mujeres que usan ACHO de tercera generación que en aquellas que usan ACHO de segunda generación 14,22,23 .…”

Section: Riesgo De Trombosis Venosaunclassified

“…El riesgo es mayor en TH del alto riesgo (homocigota o doble heterocigota para FV Leiden y Protrombina G20210A) 14,[24][25][26] . En el trabajo del Leiden Thrombophilia Study, se evaluó el riesgo relativo de un primer episodio de TEV en un grupo control de pacientes sanas que no consumían ACHO, en usuarias de ACHO sin TH, en portadoras de FV Leiden que además usaban ACHO y en mujeres homocigotas para FV Leiden que usaban ACHO.…”

Section: Riesgo De Trombosis Venosaunclassified

See 1 more Smart Citation